Last update 22 Aug 2026

SPX-301

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-claudin18.2/anti-PD-L1 bispecific antibody - Sparx Therapeutics, SPX 301, SPX-301
Target
CLDN18.2 x PDL1
Action
inhibitors
Mechanism
CLDN18.2 inhibitors(Claudin 18.2 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication-
Inactive Indication
Neoplasms
Originator Organization
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
Active Organization-
Inactive Organization
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with SPX-301
Login to view more data
100 Translational Medicine associated with SPX-301
Login to view more data
100 Patents (Medical) associated with SPX-301
Login to view more data
100 Deals associated with SPX-301
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPreclinical
United States
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
01 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free